DAC group is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-21. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
== Clinical significance == Studies on the obestatin/ghrelin ratio in the gastrointestinal tract and plasma are associated with some diseases such as irritable bowel syndrome (IBS), obesity, Prader–Willi syndrome, and type II diabetes mellitus.
L’Art Islamique en Orient – Troisième Partie (Islamic Art in the East – Part Three). It was to include 60 drawings of panelling, fountains, illuminations, of the Sokollu Mehmed Pasha Mosque in Stamboul, the Selimiye Mosque in Edirne, masterpiece of the architect Atik Sinan with timeline, plans, longitudinal and transverse sections, 12 pages of text (49 x 35.5 cm), unpublished. Faïences Décoratives de la Vieille Turquie (Decorative Faience in Ancient Turkey), Paris, Albert Morance, 1927, 29 plates including 3 double pages. Loose sketches and plans in document files, half-black canvas, first flat image illustrated in colour. La Basilique de Sainte Sophie (Αγία Σοφία) de Constantinople (The Basilica of Hagia Sophia of Constantinople), 88 drawings (ink, watercolour, gouache, gold-leaf paint): pillars, doorways, corridors, vaults, the great cupola, mosaics, plans, façades, longitudinal and transverse sections, general perspectives, marble facings, major mosaic icons. Three descriptive manuscripts by Procopius of Caesarea, by Anonymous and by the author, 1928–29. Essai de Reconstitution de la Basilique des Saints-Apôtres (Attempt to reproduce the Basilica of the Holy Apostles) 37 drawings, 1933. Mosaïques Byzantines (Byzantine Mosaics) 55 drawings, 1935. Théodora de Byzance (Theodora, Byzantine Empress) 14 drawings, 1940. Published texts L’Art du constructeur en Turquie (The Art of Construction in Turkey), 1908, Alexandria. Revue Technique d’Orient, 1910–1911, as Editor-in-Chief: miscellaneous articles.
== Cell progenitors and analogs == Dermal fibroblasts are derived from mesenchymal stem cells within the body. Like corneal fibroblasts, dermal fibroblast proliferation can be stimulated by the presence of fibroblast growth factor (FGF). Fibroblasts do not appear to be fully differentiated or specialized. After examining the CD markers of the fibroblast cells, researchers at BioMed Central discovered that these cell lack "distinctive markers" confirming that these cells can be further differentiated. One example of further differentiation of dermal fibroblasts is that upon injury, dermal fibroblasts can give rise to myofibroblasts, fibroblast cells with smooth muscle characteristics. Dermal cells differentiate into myofibroblasts by altering their actin gene expression (which is silenced in dermal fibroblasts). When dermal fibroblasts express actin, the cells can slowly contract. This contraction plays a critical role in wound healing and fibrosis. By pulling tissues closed, differentiated myofibroblasts seal the skin after an injury (thereby, preventing infection but inducing scar formation). Myofibroblasts can also be derived from non-fibroblast sources. Based on evidence of α-SMA expression from lung injuries, myofibroblasts can "arise de novo" directly from mesenchymal stem cells.
Thiamine deficiency is a medical condition of low levels of thiamine (vitamin B1). A severe and chronic form is known as beriberi. The name beriberi was possibly borrowed in the 18th century from the Sinhalese phrase බැරි බැරි (bæri bæri, "I cannot, I cannot"), owing to the weakness caused by the condition. The two main types in adults are wet beriberi and dry beriberi. Wet beriberi affects the cardiovascular system, resulting in a fast heart rate, shortness of breath, and leg swelling. Dry beriberi affects the nervous system, resulting in numbness of the hands and feet, confusion, trouble moving the legs, and pain. A form with loss of appetite and constipation may also occur. Another type, acute beriberi, found mostly in babies, presents with loss of appetite, vomiting, lactic acidosis, changes in heart rate, and enlargement of the heart. Risk factors include a diet of mostly white rice, alcoholism, dialysis, chronic diarrhea, and taking high doses of diuretics. In rare cases, it may be due to a genetic condition that results in difficulties absorbing thiamine found in food. Wernicke encephalopathy and Korsakoff syndrome are forms of dry beriberi. Diagnosis is based on symptoms, low levels of thiamine in the urine, high blood lactate, and improvement with thiamine supplementation. Treatment is by thiamine supplementation, either by mouth or by injection. With treatment, symptoms generally resolve in a few weeks. The disease may be prevented at the population level through the fortification of food. Thiamine deficiency is rare in most of the developed world.
Sources: en.wikipedia.org
=== Trapped ion mobility spectrometry === In trapped ion mobility spectrometry (TIMS), ions are held stationary (or trapped) in a flowing buffer gas by an axial electric field gradient (EFG) profile while the application of radio frequency (rf) potentials results in trapping in the radial dimension. TIMS operates in the pressure range of 2 to 5 hPa and replaces the ion funnel found in the source region of modern mass spectrometers. It can be coupled with nearly any mass analyzer through either the standard mode of operation for beam-type instruments or selective accumulation mode (SA-TIMS) when used with trapping mass spectrometry (MS) instruments. Effectively, the drift cell is prolonged by the ion motion created through the gas flow. Thus, TIMS devices do neither require large size nor high voltage in order to achieve high resolution, for instance achieving over 250 resolving power from a 4.7 cm device through the use of extended separation times. However, the resolving power strongly depends on the ion mobility and decreases for more mobile ions. In addition, TIMS can be capable of higher sensitivity than other ion mobility systems because no grids or shutters exist in the ion path, improving ion transmission both during ion mobility experiments and while operating in a transparent MS only mode.
Canada is religiously diverse, encompassing a wide range of beliefs and customs. The Constitution of Canada refers to God; however, Canada has no official church and the government is officially committed to religious pluralism. Freedom of religion in Canada is a constitutionally protected right. Rates of religious adherence have steadily decreased since the 1970s. With Christianity in decline after having once been central and integral to Canadian culture and daily life, Canada has become a post-Christian, secular state. Although the majority of Canadians consider religion to be unimportant in their daily lives, they still believe in God. The practice of religion is generally considered a private matter. According to the 2021 census, Christianity is the largest religion in Canada, with Roman Catholics representing 29.9 percent of the population having the most adherents. Christians overall representing 53.3 percent of the population, are followed by people reporting irreligion or having no religion at 34.6 percent. Other faiths include Islam (4.9%), Hinduism (2.3%), Sikhism (2.1%), Buddhism (1.0%), Judaism (0.9%), and Indigenous spirituality (0.2%). Canada has the second-largest national Sikh population, behind India.
inhalation: all intoxicative inhalants (see below) that are gases or solvent vapours that are inhaled through the trachea, as the name suggests insufflation: also known as "snorting", or "sniffing", this method involves the user placing a powder in the nostrils and breathing in through the nose, so that the drug is absorbed by the mucous membranes. Drugs that are "snorted", or "sniffed", include powdered amphetamines, cocaine, heroin, ketamine, MDMA, and snuff tobacco. Subcutaneous injection (see also the article Skin popping): injection of drug into the third lowest layer of skin. Intramuscular injection: injection of drug into a muscle. intravenous injection (see also the article Drug injection): the user injects a solution of water and the drug into a vein, or less commonly, into the tissue. Drugs that are injected include morphine and heroin, less commonly other opioids. Stimulants like cocaine or methamphetamine may also be injected. In rare cases, users inject other drugs. oral intake: caffeine, ethanol, cannabis edibles, psilocybin mushrooms, coca tea, poppy tea, laudanum, GHB, ecstasy pills with MDMA or various other substances (mainly stimulants and psychedelics), prescription and over-the-counter drugs (ADHD and narcolepsy medications, benzodiazepines, anxiolytics, sedatives, cough suppressants, morphine, codeine, opioids and others) sublingual: substances diffuse into the blood through tissues under the tongue.
Sources: en.wikipedia.org
N-Desethyletonitazene (NDE, Noretonitazene) is a benzimidazole derivative with potent opioid effects which has been sold as a designer drug. It is better known as an active metabolite of the related compound etonitazene, but has similar activity to the parent compound and has sometimes appeared as a drug of abuse in its own right, first being identified in New Zealand in 2024.
=== Clinical utility === In the FAST study, an observational case-control sequencing study including 300 persons from Germany, SPINA-GBeta differed more clearly between subjects with and without diabetes than the corresponding HOMA-Beta index.
Nuclear fission is a reaction in which the nucleus of an atom splits into two or more smaller nuclei. The fission process often produces neutrons and gamma rays, and releases a very large amount of energy even by the energetic standards of radioactive decay. The free energy released by the fission of one uranium-235 atom is about 100 million times the energy released by burning one carbon atom in air to produce CO2. Nuclear fission was discovered by chemists Otto Hahn and Fritz Strassmann and physicists Lise Meitner and Otto Robert Frisch. Hahn and Strassmann proved that a fission reaction had taken place on 19 December 1938, and Meitner and her nephew Frisch explained it theoretically in January 1939. Frisch named the process "fission" by analogy with biological fission of living cells. In their second publication on nuclear fission in February 1939, Hahn and Strassmann predicted the existence and liberation of additional neutrons during the fission process, opening up the possibility of a nuclear chain reaction by assembling a critical mass of fissile material. For heavy nuclides, it is an exothermic reaction which releases large amounts of energy both as electromagnetic radiation and as kinetic energy of the fragments (heating the bulk material where fission takes place). Like nuclear fusion, for fission to produce energy, the total binding energy of the resulting elements must be greater than that of the starting element. The fission barrier must also be overcome.
=== Pregnancy === HLA-G plays a role in immune tolerance in pregnancy, being expressed in the placenta by extravillous trophoblast cells (EVT), while the classical MHC class I genes (HLA-A and HLA-B) are not. As HLA-G was first identified in placenta samples, many studies have evaluated its role in pregnancy disorders, such as preeclampsia and recurrent pregnancy loss. Its downregulation is related to HLA-A and -B downregulation results in protection from cytotoxic T cell responses, but would in theory result in a missing self response by natural killer cells. HLA-G is a ligand for natural killer (NK) cell inhibitory receptor KIR2DL4, and therefore expression of this HLA by the trophoblast defends it against NK cell-mediated death. The presence of soluble HLA-G (sHLA-G) in embryos is associated with better pregnancy rates. In order to optimize pregnancy rates, there is significant evidence that a morphological scoring system is the best strategy for the selection of embryos. However, presence of soluble HLA-G might be considered as a second parameter if a choice has to be made between embryos of morphologically equal quality.
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.